|
A clinical trial evaluating ABX-EGF (a monoclonal antibody) given to patients with prostate cancer with or without tumor in other parts of the body. Clinical Trials Information presented on Clinical Trials Search is not designed to be a substitute for proven healthcare advice, travels to or treatment by using a genuine medical doctor. We are not physicians. Always confer with your doctor on A clinical trial evaluating ABX-EGF (a monoclonal antibody) given to patients with prostate cancer with or without tumor in other parts of the body. conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. A clinical trial evaluating ABX-EGF (a monoclonal antibody) given to patients with prostate cancer with or without tumor in other parts of the body. Clinical research trials and A clinical trial evaluating ABX-EGF (a monoclonal antibody) given to patients with prostate cancer with or without tumor in other parts of the body. healthcare trials take place in many of cities across the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the effectiveness of new drugs. The function of the studies / undertakings is to answer specific human medical questions. Clinical trials are a popular means for mDs, government agencies, and private sector companies to find treatments for all forms of conditions, including A clinical trial evaluating ABX-EGF (a monoclonal antibody) given to patients with prostate cancer with or without tumor in other parts of the body.. A clinical trial evaluating ABX-EGF (a monoclonal antibody) given to patients with prostate cancer with or without tumor in other parts of the body. Clinical Trials and other clinical trials allow for volunteers to access medical treatment alternatives before they are available to the masses. Many times the test subjects undergo treatment for without cost, and occasionally they are compensated for their time. Occasionally there is a cost for a A clinical trial evaluating ABX-EGF (a monoclonal antibody) given to patients with prostate cancer with or without tumor in other parts of the body. clinical trial. Test subjects oftentimes recieve the best healthcare possible for their A clinical trial evaluating ABX-EGF (a monoclonal antibody) given to patients with prostate cancer with or without tumor in other parts of the body. condition. Hazards are a reality, nonetheless, and might include additional or frequent doctor trips, healthcare hazards (perhaps life-jeopardizing), and/or the treatment being ineffective. Trials are federally regulated with rigid guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > A clinical trial evaluating ABX-EGF (a monoclonal antibody) given to patients with prostate cancer with or without tumor in other parts of the body.  A clinical trial evaluating ABX-EGF (a monoclonal antibody) given to patients with prostate cancer with or without tumor in other parts of the body.
A clinical trial evaluating ABX-EGF (a monoclonal antibody) given to patients with prostate cancer with or without tumor in other parts of the body.
For Condition: Prostate Cancer
Status: Recruiting
Sponsor(s): Abgenix , Immunex Corporation
Synopsis: A clinical trial examining the safety and effectiveness of ABX-EGF when given to patients with prostate cancer with or without tumor in other parts of the body. Patients will be treated for a maximum of 48 doses (6 treatment courses; 8 doses per course) or until evidence of progressive disease.
Details:
Eligibility:
Study Type: Interventional, Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/
Genders: Male
Protocol Entry Criteria: Inclusion Criteria: - Male 18 years of age or older - Has tumor tissue available for diagnostics - Failed front line luteinizing hormone-releasing hormone analogue (LHRH) such as leuprolide or goserelin, or failed orchiectomy, as evidenced by disease progression. Patients must continue on a LHRH analogue (unless the patient had an orchiectomy) throughout the course of the study - ECOG score of 0 or 1 Exclusion Criteria: - Any prior chemotherapy for prostate cancer besides hormonal therapy (including no prior EGFr targeting agent) - Prior history of cancer other than prostate carcinoma within the past 5 years that has required treatment or been active (prior basal cell carcinoma is allowed) - Known to be HIV positive - Myocardial infarction within one year prior to entering the study
Total Enrollment: 50
Location and Contact Information:
University of Pittsburgh Cancer Institute, Hillman Cancer Center *Recruiting*
Pittsburgh, Pennsylvania, 15232
United States
Recruiting Janie Hofacker 412-647-8252
Fox Chase Cancer Center *Recruiting*
Philadelphia, Pennsylvania, 19111
United States
Recruiting Central Referral 888-369-2427
Urology San Antonio Research *Recruiting*
San Antonio, Texas, 78229
United States
Recruiting Beatrice Escamilla 210-617-4116
Advanced Research Institute *Recruiting*
New Port Richey, Florida, 34652
United States
Recruiting Kristin White 727-842-9561
Stanford Medical Center *Recruiting*
Stanford, California, 94303
United States
Recruiting Sandy Srinivas 650-725-2078
University of Washington *Recruiting*
Seattle, Washington, 98109
United States
Recruiting Karlee Olson 206-288-1349
UCLA School of Medicine *Recruiting*
Los Angeles, California, 90095
United States
Recruiting Nazy Zomorodian 310-794-7704
Madigan Army Medical Center *Recruiting*
Tacoma, Washington, 98431
United States
Recruiting Shari Aynes 253-968-3710
University of Alabama at Birmingham *Recruiting*
Birmingham, Alabama, 35294
United States
Recruiting Andres Forero 205-934-7167
Additional Information:
Study ID Numbers: ABX-0310; ABX-EGF
Study Start Date: April 2003
Record last reviewed: June 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00061126
Other Prostate Cancer Studies:
1. A clinical trial evaluating ABX-EGF (a monoclonal antibody) given to patients with prostate cancer with or without tumor in other parts of the body.
2. Soy Protein Supplement in Preventing Prostate Cancer in Patients With Elevated Prostate-Specific Antigen Levels
3. Clinical Trial for Prostate Cancer
4. Selenium in Preventing Cancer in Patients With Neoplasia of the Prostate
5. Selenium and Vitamin E Cancer Prevention Trial (SELECT)
Related Studies:
Other Prostate Cancer Clinical Trials
Other California Clinical Trials
Other Stanford Clinical Trials
A clinical trial evaluating ABX-EGF (a monoclonal antibody) given to patients with prostate cancer with or without tumor in other parts of the body.
|
|
|
|
|
|
|
|
